TUFTS CSDD IMPACT REPORTS
Analysis and insight into critical drug development issues. Cutting edge information. Original research. Your most reliable guide to drug development.
Tufts CSDD Impact Reports are a bi-monthly subscription-based publication presenting original research, hard-hitting authoritative data, analysis, and insights on essential topics in drug development. Concise by design, the results and insights presented in Tufts CSDD Impact Reports have been cited extensively in the trade press and in The New York Times, Boston Globe, Wall Street Journal, Forbes, Time Magazine, and the New England Journal of Medicine, among others.
Tufts CSDD Impact Reports present trusted research, objective evidence, and insights:
-
Charts and tables present key points and synthesized analysis, letting you focus on major strategic findings -
Clear and concise bulleted takeaways save you time deciphering extensive text -
Explanatory sidebars and definitions ensure a shared understanding of key concepts and terms
Pricing:
Annual Individual Subscription
Tufts CSDD Impact Report Annual Individual Subscription: $675 USD Details: Six (6) Bi-monthly Issues, Electronic PDF Delivery. Purchase Individual Subscription
*Subscriber will receive six (6) reports starting the current issue from purchase date. This subscription is not archive access: older issues can be purchased for an additional cost * 
Single Issue
Tufts CSDD Impact Report Single (1) Issue: $150 USD Details: One (1) Issue, Electronic PDF Delivery. Purchase Single Issue
Corporate Multi-User Subscription
We offer both individual and corporate subscriptions to Tufts CSDD Impact Reports. Corporate subscriptions provide everyone in your department or organization immediate access to these timely reports. Priced to be cost effective, corporate subscriptions offer a significant volume discount off the annual individual subscription fee. For more information, please contact us through email at csdd@tufts.edu. Purchase Corporate Multi-User SubscriptionDelivery Process:
Orders are processed manually within 24 hours of receipt, during the regular business hours of 9AM to 5PM ET Monday–Friday, excluding university holidays. Orders placed outside of business hours will be processed on the following business day. Reports are sent as an electronic attachment (PDF) along with an email receipt. If you do not receive your report within 24 hours, please contact us.Request a copy of one of our recent Impact Reports:
2024
Participation burden for patients in clinical trials is rising, especially in non-oncology studies
September/October Vol. 26 No. 5
Dollar value of one day delay in drug development is now 20% of blockbuster era levels.
July/August Vol. 26 No. 4
Use of digital endpoints to collect clinical trial data is rapidly increasing.
May/June Vol. 26 No. 3
Workplace microaggressions associated with staff turnover and poor performance.
March/April Vol. 26 No. 2
Global site activation and patient enrollment strategies produce mixed results.
January/February Vol. 26 No. 1
2023
Number of biotech products in late-stage clinical trials has quadrupled during the past decade.
November/December Vol. 25 No. 6
Select socioeconomic factors highly associated with clinical trial attitudes and interest.
September/October Vol. 25 No. 5
Approximately half of clinical trials use risk based quality management components
July/August Vol. 25 No. 4
Protocol design scope and execution burden continue to rise, most notably in Phase III
May/June Vol. 25 No. 3
Prevalence and mean number of protocol amendments increasing across all phases
March/April Vol. 25 No. 2
Global sites optimistic about the future of clinical trials despite ongoing challenges
January/February Vol. 25 No. 1
2022
Top CROs gain market share, close record number of M&A deals, improve productivity
November/December Vol. 24 No. 6
DCTs Substantially Increase Financial Value Based on Key Performance Indicators
September/October Vol. 24 No. 5
Innovations Supporting Clinical Trial Execution Take Nearly Six Years to Adopt
July/August Vol. 24 No. 4
In Europe, Demographic Under-Representation in Clinical Trials Persists
May/June Vol. 24 No. 3
Cost Variation and Mis-Estimation Characterize Clinical Trial Budgets, Particularly in Early Phases.
March/April Vol. 24 No. 2
The Incidence of Protocol Deviations and Amendments is High and Rising
January/February Vol. 24 No. 1
2021
New Study Finds Site Personnel Race and Ethnicity Highly Correlated with Diversity of Patients Enrolled
November/December Vol. 23 No. 6
Clinical Teams Working Remotely During the COVID-19 Pandemic Remain Highly Productive
September/October Vol. 23 No. 5
Biotech R&D Spending Grew by More Than 3x the Rate of Total Industry Spend in 2001-20 July/August Vol. 23 No. 4 SUMMARY | Press Release
Protocol Complexity and Patient Enrollment Intensify Challenges in Oncology Trials May/June Vol. 23 No. 3 SUMMARY | Press Release
Planned and Unplanned Mid-Study Updates Pose Major Challenge to Clinical Trial Timelines March/April Vol. 23 No. 2 SUMMARY | Press Release
Rising Protocol Design Complexity is Driving Rapid Growth in Clinical Trial Data Volume January/February Vol. 23 No. 1 SUMMARY | Press Release
2020
Global Clinical Trials Transition to Decentralized Models Abruptly, in Nuanced WaysNovember/December Vol. 22 No. 6 SUMMARY | Press Release
New Anti-infective Drugs Had a 14% Speed Advantage vs. Other Drugs During 2000-19 September/October Vol. 22 No. 5 SUMMARY | Press Release
Faster New Drug Approval Phases Are More Than Offset by Longer Clinical Times in U.S July/August Vol. 22 No. 4 SUMMARY | Press Release
New Benchmarks Quantify Demographic Under-Representation in Clinical Trials May/June Vol. 22 No. 3 SUMMARY | Press Release
Drug Developers Respond to Evolving Clinical Data Demands with New Strategies, Tactics March/April Vol. 22 No. 2 SUMMARY | Press Release
New Global Recruitment Performance Benchmarks Yield Mixed Results January/February Vol. 22 No. 1 SUMMARY | Press Release
2019
Vendor Qualification Process Volume and Complexity Require Substantial Time and Cost November/December Vol. 21 No. 6 SUMMARY | Press Release
Cancer Drug Approvals Grew from 4% of U.S. Total in the 1980s to 27% in 2010-18 September/October Vol. 21 No. 5 SUMMARY | Press Release
Growth in Rare Disease R&D in Challenging Development Strategy and Execution July/August Vol. 21 No. 4 SUMMARY | Press Release
Adoption of Artificial Intelligence is High Across Drug Development May/June Vol. 21 No. 3 SUMMARY | Press Release
Outsourcing Outpaces Internal Spending but Remains Tactical and Reactive March/April Vol. 21 No. 2 SUMMARY | Press Release
U.S. continues to Lead New Drug R&D, but Asia-Pacific is Starting to Rise January/February Vol. 21 No. 1 SUMMARY | Press Release
2018
Global Biotech Product Development Continues its Multi-Decade SurgeNovember/December Vol. 20 No. 6
SUMMARY | Press Release
CNS Drugs Take 20% Longer to Develop and to Approve vs. Non-CNS DrugsSeptember/October Vol. 20 No. 5
SUMMARY | Press Release
Rising Protocol Complexity is Hindering Study Performance, Cost, and EfficiencyJuly/August, Vol. 20 No. 4SUMMARY | Press Release
Patent-to-launch Time for Orphan Drugs is 2.3 Years Longer vs. Other DrugsMay/June, Vol. 20 No. 3SUMMARY | Press Release
Clinical Site Initiation Process Remains Lengthy and Highly InefficientMarch/April, Vol. 20 No. 2SUMMARY | Press Release
Clinical Data Volume and Diversity Pose Increasing Challenges and DelaysJan/Feb, Vol. 20 No. 1SUMMARY | Press Release
2017
Real World Evidence Use in Clinical & Post-Approval Research Set to ExpandNov/Dec, Vol. 19 No.6SUMMARY | Press Release
Cardiovascular Drug Approval Rate in the U.S. Fell as Development Time RoseSep/Oct, Vol. 19 No.5SUMMARY | Press Release
Abuse-Deterrent Opioid Development and Uptake Are Tied to Efficacy and Regulatory/Payer PoliciesJul/Aug, Vol. 19 No. 4SUMMARY | Press Release
Biotech Products Accounted for 35% of All New FDA Approvals in 2000-16May/Jun, Vol. 19 No. 3SUMMARY | Press Release
Approval Time for 505(b)(2) Drugs is Nearly Five Months Longer Than for NMEsMar/Apr, Vol. 19 No. 2SUMMARY | Press Release
Poor Physician and Nurse Engagement Driving Low Patient RecruitmentJan/Feb, Vol. 19 No. 1SUMMARY | Press Release
2016
Pediatric Regulatory Science, Clinical Trial Networks Hold Promise for StudiesNov/Dec, Vol. 18 No. 6SUMMARY | Press Release
Diabetes Drug Development is Riskier Compared to All Drug DevelopmentSep/Oct, Vol. 18 No. 5SUMMARY | Press Release
Global Regenerative Medicine Market is Poised for Strong GrowthJul/Aug, Vol. 18 No. 4SUMMARY | Press Release
Expected Growth in PBM Exclusion Lists Poses a Challenge to Drug DevelopersMay/June, Vol. 18 No. 3SUMMARY | Press Release
Promise of Immuno-Oncology Therapies is Boosting R&D Funding, AlliancesMarch/April, Vol. 18 No. 2SUMMARY | Press Release
Amendments Reduce Number of Patients, But at High Cost, Longer Study TimesJanuary/February, Vol. 18 No. 1SUMMARY | Press Release
2015
First-in-Class Drugs in Competitive Development Races With Later EntrantsNovember/December, Vol. 17 No. 6SUMMARY | Press Release
Adverse Drug Event Reporting in U.S. Beset by Incompleteness and InaccuracySeptember/October, Vol. 17 No.5SUMMARY | Press Release
Vaccine Products in the R&D Pipeline Have More Than Tripled Since 2005July/August 2015, Vol. 17 No. 4SUMMARY | Press Release
Personalized Medicine Gains Traction But Still Faces Multiple ChallengesMay/June 2015, Vol. 17 No. 3SUMMARY | Press Release
Biosimilars Entering the U.S. Market Are Likely to Face Multiple ChallengesMarch/April 2015, Vol. 17 No. 2SUMMARY | Press Release
High Turnover, Protocol Noncompliance Plague the Global Site LandscapeJanuary/February 2015, Vol. 17 No. 1SUMMARY | Press Release
2014
CNS Drugs Take Longer to Develop, Have Lower Success Rates, Than Other DrugsNovember/December 2014, Vol. 16 No. 6SUMMARY | Press Release
Protocol Design Optimization Starting to Improve Study PerformanceSeptember/October 2014, Vol. 16 No. 5SUMMARY | Press Release
Patients Face New Challenges Accessing a Growing Number of Orphan DrugsJuly/August 2014, Vol. 16 No. 4SUMMARY | Press Release
Collaboration & Risk-Sharing Programs Experience Longer Development TimesMay/June 2014, Vol. 16 No. 3SUMMARY | Press Release
Drug Sponsors Tread Cautiously Using Social Media to Aid Clinical ResearchMarch/April 2014, Vol. 16 No. 2SUMMARY | Press Release
New Breakthrough Therapy Designation Program Aims to Cut Clinical Trial TimeJanuary/February 2014, Vol. 16 No. 1SUMMARY | Press Release
2013
Biotech Products in Big Pharma Clinical Pipelines Have Grown DramaticallyNovember/December 2013, Vol. 15 No. 6SUMMARY | Press Release
Causes of Clinical Failures Vary Widely by Therapeutic, Phase of StudySeptember/October 2013, Vol. 15 No. 5SUMMARY | Press Release
Annual Approvals for Neglected Diseases Rose from 2.6 in 2000-08 to 5 in 2009-12July/August 2013, Vol. 15 No. 4SUMMARY | Press Release
Clinical Success Rates for New Cancer Drugs Double While More Enter TestingMay/June 2013, Vol. 15 No. 3SUMMARY | Press Release
Global Site Landscape Remains Highly Fragmented with Variable PerformanceMarch/April 2013, Vol. 15 No. 2SUMMARY | Press Release
89% of Trials Meet Enrollment, but Timelines Slip, Half of Sites Under-EnrollJanuary/February 2013, Vol. 15 No. 1SUMMARY | Press Release
2012
One in Five Procedures Generates Extraneous Clinical Trials DataNovember/December 2012, Vol. 14 No. 6SUMMARY | Press Release
Oncology Drugs Get Faster Approvals Than Non-Oncology Drugs in U.S.September/October 2012, Vol. 14 No. 5SUMMARY | Press Release
U.S. Offers Patients Faster, Greater Access to Cancer Drugs Than EuropeJuly/August 2012, Vol. 14 No. 4SUMMARY | Press Release
User Fee Era in U.S. Currently Poses Mixed Regulatory Burden for SponsorsMay/June 2012, Vol. 14 No. 3SUMMARY | Press Release
Pace of CNS Drug Development and FDA Approvals Lags Other Drug ClassesMarch/April 2012, Vol. 14 No. 2SUMMARY | Press Release
Study Monitor Workload High & Varied with Wide Disparity by Global RegionJanuary/February 2012, Vol. 14 No. 1SUMMARY | Press Release
TUFTS CSDD IMPACT REPORTS 1999-2011
Explore the electronic archive of Tufts CSDD Impact Reports from 1999 - 2011.
View Catalog